

10/564,637

STM- Structure Search

9/26/07

=> d his

(FILE 'HOME' ENTERED AT 12:57:19 ON 26 SEP 2007)


FILE 'REGISTRY' ENTERED AT 12:58:02 ON 26 SEP 2007

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FULL

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> => d his

(FILE 'HOME' ENTERED AT 12:57:19 ON 26 SEP 2007)

FILE 'REGISTRY' ENTERED AT 12:58:02 ON 26 SEP 2007


L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FULL
L4 STRUCTURE UPLOADED
L5 0 S L4
L6 0 S L4 FULL

=> d l4

L4 HAS NO ANSWERS

L4 STR

10/564,637



Structure attributes must be viewed using STN Express query preparation.

=>

10/564,637

=> d ibib abs hitstr 1-87

STM- Structure Search

9/28/07

L4 ANSWER 1 OF 87 CAPLUS COPYRIGHT 2007 ACS on STM

ACCESSION NUMBER: 2007:941813 CAPLUS

DOCUMENT NUMBER: 147:274950

TITLE: Cancer-associated mutations and polymorphisms of ERBB2, and methods of diagnostic and therapeutic uses

INVENTOR(S): Culver, Kenneth Wayne; Zhu, Jian; Lilleberg, Stan

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 99pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007095038	A2	20070823	WO 2007-US3305	20070207
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

US 2006-771907P

P 20060209

AB This invention relates generally to the anal. testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the ERBB2 gene. The invention provides new ERBB2 mutations and SNPs (single nucleotide polymorphisms), useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the ERBB2 mutations of the invention, expression vectors encoding the ERBB2 mutant polypeptides of the invention and organisms that express the ERBB2 mutant and polymorphic polynucleotides and/or ERBB2 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the ERBB2 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.

IT 292618-32-7, Gimatcan

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cancer-associated mutations and polymorphisms of ERBB2, and methods of diagnostic and therapeutic uses)


RN 292618-32-7 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde, 4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-[O-(1,1-dimethylethyl)oxime], [C(E),4S]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


Double bond geometry as shown.

10/564,637



RN 292620-90-7 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde,
4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-[O-(1,1-
dimethylethyl)oxime], (4S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




X L4 ANSWER 30 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:759299 CAPLUS
DOCUMENT NUMBER: 145:356971
TITLE: Synthesis and Cytotoxic Activity of Polyamine
Analogues of Camptothecin
AUTHOR(S): Dallavalle, Sabrina; Giannini, Giuseppe; Alloatti,
Domenico; Casati, Andrea; Marastoni, Elena; Musso,
Loana; Merlini, Lucio; Morini, Gabriella; Penco,
Sergio; Pisano, Claudio; Tinelli, Stella; De Cesare,
Michelandrea; Beretta, Giovanni Luca; Zunino, Franco
CORPORATE SOURCE: Dipartimento di Scienze Molecolari Agroalimentari,
Universita di Milano, Milan, 20133, Italy
SOURCE: Journal of Medicinal Chemistry (2006), 49(17),
5177-5186
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:356971
AB A number of derivs. of camptothecin with a polyamine chain linked to position
7 of camptothecin via an amino, imino, or oxyiminomethyl group were
synthesized and tested for their biol. activity. All compds. showed
marked growth inhibitory activity against the H460 human lung carcinoma

cell line. In particular, the iminomethyl derivs. where the amino groups of the chain were protected with Boc groups exhibited a high potency, with IC50 values of .apprx.10-8 M. The pattern of DNA cleavage in vitro and the persistence of the cleavable ternary complex drug-DNA-topoisomerase I observed with polyamine conjugates containing free amino groups support a contribution of specific drug interaction with DNA as a determinant of activity. Modeling of one compound in the complex with topoisomerase 1 and DNA is consistent with this hypothesis. The lack of a specific correlation between stabilization of the cleavable complex and growth inhibition likely reflects multiple factors including the cellular pharmacokinetic behavior related to the variable lipophilicity of the conjugate, and the nature and linkage of the polyamine moiety.

IT 910482-66-5
 RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
 (preparation and antitumor and topoisomerase 1 inhibitory activity of polyamine analogs of camptothecin)
 RN 910482-66-5 CAPLUS
 CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde, 4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-[O-(2-aminoethyl)oxime], monohydrochloride, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



● HCl

IT 828262-55-1P 828263-70-3P 910482-73-4P
 910482-74-5P 910482-75-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and antitumor and topoisomerase 1 inhibitory activity of polyamine analogs of camptothecin)
 RN 828262-55-1 CAPLUS
 CN 2,6,11,15-Tetraazahexadec-15-enoic acid, 6,11-bis[(1,1-dimethylethoxy)carbonyl]-16-[(4S)-4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

10/564,637

and an antiproliferative agent simultaneously or within 14 days of each other in amts. sufficient to treat the patient.

IT 292618-32-7, Gimatecan

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(chlorpromazine compound-antiproliferative drug antitumor combination)

RN 292618-32-7 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde, 4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-[O-(1,1-dimethylethyl)oxime], [C(E),4S]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



Inventor

L4 ANSWER 55 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:58207 CAPLUS

DOCUMENT NUMBER: 142:156197

TITLE: Preparation of 7-polyaminoalkyl(oxy)iminomethylcamptot
hecins bearing protective groups for use in
pharmaceutical compositions as topoisomerase-I
inhibitors

INVENTOR(S): Giannini, Giuseppe; Penco, Sergio; Tinti, Maria
Ornella; Pisano, Claudio; Vesci, Loredana; Merlini,
Lucio; Zunino, Franco

PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.,
Italy; Istituto Nazionale Per Lo Studio E La Cura Dei
Tumori

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005431	A2	20050120	WO 2004-IT374	20040706
WO 2005005431	A3	20050224		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,			


SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

AU 2004255949	A1	20050120	AU 2004-255949	20040706
CA 2532193	A1	20050120	CA 2004-2532193	20040706
EP 1656380	A2	20060517	EP 2004-745199	20040706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004012499	A	20060919	BR 2004-12499	20040706
CN 1918170	A	20070221	CN 2004-80019789	20040706
JP 2007518688	T	20070712	JP 2006-520107	20040706
IN 2005KN02727	A	20061110	IN 2005-KN2727	20051227
MX 2006PA00471	A	20060920	MX 2006-PA471	20060111
US 2007043067	A1	20070222	US 2006-564637	20060810

PRIORITY APPLN. INFO.:

IT 2003-RM344 A 20030714
WO 2004-IT374 W 20040706

OTHER SOURCE(S): CASREACT 142:156197; MARPAT 142:156197
GI



AB Camptothecin derivs., such as I [X = NR; R = N-protected-aminoalkyl, N-protected-aminoalkoxy, N-protected-polyaminoalkyl, N-protected-polyaminoalkoxy], which are characterized by the presence of polyamine substituents on the imine/oxime residue, such amine groups being in turn protected by suitable protective groups, were prepared for therapeutic use as topoisomerase I inhibitors. These camptothecins are claimed for use as agents for the treatment of tumors and viral and parasite infections. Thus, camptothecin derivative ST 2544 I [X = :N(CH₂)₃N(CO₂CMe₃)(CH₂)₄N(CO₂CMe₃)(CH₂)₃NHCO₂CMe₃] was prepared via an imidation reaction with 81% yield of 7-formylcamptothecin I (X = :O) with the corresponding BOC-protected spermine derivative, H₂N(CH₂)₃N(CO₂CMe₃)(CH₂)₄N(CO₂CMe₃)(CH₂)₃NHCO₂CMe₃, using Yb(OSO₂CF₃)₃ in CH₂Cl₂. The prepared camptothecin derivs. were assayed for cytotoxic effect on *Saccharomyces cerevisiae* cells and for antitumor activity against MKN-28 human gastric carcinoma.

IT 827603-86-1P 827603-90-7P 827603-94-1P
827603-98-5P 827604-02-4P 827604-06-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of


7-polyaminoalkyl(oxy)iminomethylcamptothecin

s bearing protective groups with topoisomerase-I inhibiting activity for use in pharmaceutical compns. as anticancer, antiviral and antiparasitic agents)

RN 827603-86-1 CAPLUS

CN Carbamic acid, [4-[[[(1,1-dimethylethoxy)carbonyl]amino]butyl][3-[[[(4S)-4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl]methylene]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




● Na

RN 88298-98-0 CAPLUS

CN L-Leucine, N-[(4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)carbonyl]-, ethyl ester, (S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 87 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:54274 CAPLUS

DOCUMENT NUMBER: 98:54274

TITLE: 7-Substituted camptothecin derivatives

INVENTOR(S): Miyasaka, Tadashi; Mutai, Masahiko; Sawada, Seigo; Nokata, Kenichiro

PATENT ASSIGNEE(S): Yakult Honsha Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 43 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 56692	A1	19820728	EP 1982-300104	19820108
EP 56692	B1	19850814		
R: BE, CH, DE, FR, GB, IT, SE				
JP 57116075	A	19820719	JP 1981-1148	19810109

10/564,637

JP 62047191	B	19871006		
JP 57116076	A	19820719	JP 1981-1149	19810109
JP 62047192	B	19871006		
JP 57185285	A	19821115	JP 1981-67594	19810507
JP 62047189	B	19871006		
US 4399276	A	19830816	US 1981-336494	19811231
CA 1177487	A1	19841106	CA 1982-393558	19820104
PRIORITY APPLN. INFO.:			JP 1981-1148	A 19810109
			JP 1981-1149	A 19810109
			JP 1981-67594	A 19810507
OTHER SOURCE(S):		CASREACT 98:54274; MARPAT 98:54274		
GI				




AB 7-Substituted camptothecins I [R = CHO, CH₂OR₁, CH(OR₁)₂, [R₁ = C1-6-alkyl or Ph(CH₂)₁₋₃], CH:NOH or CH:NNR₂R₃ (R₂, R₃ = H, C1-6-alkyl, aryl, CONH₂, acyl, aminoalkyl or amidino, or R₂R₃N = heterocyclyl)], which have anti-tumor activity (no data), were prepared from I (R = CH₂OH) (II). Thus, 100 mg II dissolved in 50 mL pyridine and 50 mL DMF was treated with 200 mg PhCH₂COCl for 6 h at 90-100° to give 56.5% I (R = CH₂O₂CCH₂Ph) and 19.1% I (R = CHO).

IT 84018-02-0P 84018-03-1P 84018-04-2P
84018-05-3P 84018-06-4P 84018-07-5P
84018-08-6P 84018-09-7P 84018-10-0P
84018-11-1P 84018-12-2P 84018-13-3P
84018-14-4P 84018-15-5P 84018-16-6P
84018-17-7P 84018-18-8P 84018-19-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of).

RN 84018-02-0 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde,
4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-oxime, (4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




10/564,637

RN 84018-03-1 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde,
4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-hydrazone, (S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 84018-04-2 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde,
4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-(methylhydrazone),
(S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 84018-05-3 CAPLUS


CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde,
4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-(phenylhydrazone),
(S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 84018-06-4 CAPLUS
 CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde,
 4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-[(2,4-
 dinitrophenyl)hydrazone], (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 84018-07-5 CAPLUS
 CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
 4-ethyl-4-hydroxy-11-[[[(4-methyl-1-piperazinyl)imino]methyl]-,
 monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.


10/564,637



● HCl

RN 84018-08-6 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
4-ethyl-4-hydroxy-11-[[[(4-methyl-1-piperazinyl)imino]methyl]-, (S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 84018-09-7 CAPLUS
CN Pyridinium, 1-[2-[[[(4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methylene]hydrazino]-2-oxoethyl]-, chloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

10/564,637




● Cl⁻

RN 84018-10-0 CAPLUS

CN Hydrazinecarbothioamide, 2-[(4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methylene]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 84018-11-1 CAPLUS

CN Hydrazinecarboxamide, 2-[(4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methylene]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

10/564,637




RN 84018-12-2 CAPLUS

CN Glycine, N,N-dimethyl-, [(4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methylene]hydrazide, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



● HCl


RN 84018-13-3 CAPLUS

CN Ethanaminium, 2-[[[(4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methylene]hydrazino]-N,N,N-trimethyl-2-oxo-, chloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

10/564,637




● Cl⁻

RN 84018-14-4 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
11-[[(2,4-dioxo-1-imidazolidinyl)imino]methyl]-4-ethyl-4-hydroxy-, (S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 84018-15-5 CAPLUS

CN 4-Pyridinecarboxylic acid, [(4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methylene]hydrazide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


10/564,637



RN 84018-16-6 CAPLUS

CN Hydrazinecarboxamide, 2-[(4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methylene]-N-phenyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 84018-17-7 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[(3-oxazolidinylimino)methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 84018-18-8 CAPLUS

10/564,637

CN Benzenesulfonic acid, 4-methyl-, [(4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methylene]hydrazide, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 84018-19-9 CAPLUS

CN Hydrazinecarboximidamide, 2-[[[(4S)-4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methylene]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



=> d his

(FILE 'HOME' ENTERED AT 13:43:25 ON 26 SEP 2007)

FILE 'REGISTRY' ENTERED AT 13:43:36 ON 26 SEP 2007

L1 STRUCTURE UPLOADED

L2 24 S L1

L3 320 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:44:03 ON 26 SEP 2007


L4 87 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR

10/564,637



Structure attributes must be viewed using STN Express query preparation.

=>